A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine
A Trial Comparing NNC0148-0287 C (Insulin 287) Versus Insulin Glargine U100, Both in Combination With Metformin, With or Without DPP4 Inhibitors and With or Without SGLT2 Inhibitors, in Basal Insulin Treated Subjects With Type 2 Diabetes Mellitus
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 2E1
- Novo Nordisk Investigational Site
-
-
British Columbia
-
Surrey, British Columbia, Canada, V3Z 2N6
- Novo Nordisk Investigational Site
-
Vancouver, British Columbia, Canada, V5Y 3W2
- Novo Nordisk Investigational Site
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 2Y9
- Novo Nordisk Investigational Site
-
-
Ontario
-
Brampton, Ontario, Canada, L6S 0C6
- Novo Nordisk Investigational Site
-
Concord, Ontario, Canada, L4K 4M2
- Novo Nordisk Investigational Site
-
Etobicoke, Ontario, Canada, M9R 4E1
- Novo Nordisk Investigational Site
-
Hamilton, Ontario, Canada, L8M 1K7
- Novo Nordisk Investigational Site
-
Markham, Ontario, Canada, L3P 7P2
- Novo Nordisk Investigational Site
-
Sarnia, Ontario, Canada, N7T 4X3
- Novo Nordisk Investigational Site
-
-
-
-
-
Broumov, Czechia, 550 01
- Novo Nordisk Investigational Site
-
Holešov, Czechia, 76901
- Novo Nordisk Investigational Site
-
Hranice, Czechia, 75301
- Novo Nordisk Investigational Site
-
Trutnov, Czechia, 541 01
- Novo Nordisk Investigational Site
-
-
-
-
-
Falkensee, Germany, 14612
- Novo Nordisk Investigational Site
-
Hamburg, Germany, 22607
- Novo Nordisk Investigational Site
-
Ludwigshafen, Germany, 67059
- Novo Nordisk Investigational Site
-
Münster, Germany, 48145
- Novo Nordisk Investigational Site
-
Oldenburg I. Holst, Germany, 23758
- Novo Nordisk Investigational Site
-
Saint Ingbert-Oberwürzbach, Germany, 66386
- Novo Nordisk Investigational Site
-
-
-
-
-
Bergamo, Italy, 24127
- Novo Nordisk Investigational Site
-
Catanzaro, Italy, 88100
- Novo Nordisk Investigational Site
-
Milano, Italy, 20122
- Novo Nordisk Investigational Site
-
Milano, Italy, 20132
- Novo Nordisk Investigational Site
-
Roma, Italy, 00161
- Novo Nordisk Investigational Site
-
-
-
-
California
-
Walnut Creek, California, United States, 94598
- Novo Nordisk Investigational Site
-
-
Georgia
-
Roswell, Georgia, United States, 30076
- Novo Nordisk Investigational Site
-
-
Idaho
-
Idaho Falls, Idaho, United States, 83404-7596
- Novo Nordisk Investigational Site
-
-
Nevada
-
Las Vegas, Nevada, United States, 89148
- Novo Nordisk Investigational Site
-
-
New Hampshire
-
Nashua, New Hampshire, United States, 03063
- Novo Nordisk Investigational Site
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37404
- Novo Nordisk Investigational Site
-
Chattanooga, Tennessee, United States, 37411
- Novo Nordisk Investigational Site
-
Nashville, Tennessee, United States, 37203
- Novo Nordisk Investigational Site
-
-
Texas
-
Dallas, Texas, United States, 75230
- Novo Nordisk Investigational Site
-
Dallas, Texas, United States, 75390-9302
- Novo Nordisk Investigational Site
-
Dallas, Texas, United States, 75226
- Novo Nordisk Investigational Site
-
Dallas, Texas, United States, 75231
- Novo Nordisk Investigational Site
-
-
Washington
-
Renton, Washington, United States, 98057
- Novo Nordisk Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Male or female, aged 18-75 years (both inclusive) at the time of signing informed consent.
- Diagnosed with type 2 diabetes mellitus greater than or equal to 180 days prior to the day of screening.
- Glycosylated haemoglobin (HbA1c) of 7.0-10.0% (53.0-85.8 mmol/mol) (both inclusive) as assessed by central laboratory.
- Treated with once daily or twice daily basal insulin analogue (insulin degludec, insulin detemir, insulin glargine U100 or U300, total daily dose of 10-50 U, both inclusive) greater than or equal to 90 days prior to the day of screening.
Stable daily dose(s) for 90 days prior to the day of screening of any of the following antidiabetic drug(s) or combination regime(s):
- Any metformin formulations greater than or equal to 1500 mg or maximum tolerated or effective dose (as documented in subject's medical records).
- Free or fixed combination therapy: Metformin as outlined above with or without dipeptidyl peptidase 4 inhibitors (DPP4i) with or without sodium-glucose cotransporter 2 inhibitors (SGLT2i) is allowed: 1) DPP4i (greater than or equal to half of the maximum approved dose according to local label or maximum tolerated or effective dose); 2) SGLT2i (greater than or equal to half of the maximum approved dose according to local label or maximum tolerated or effective dose.
- Body mass index (BMI) less than or equal to 40.0 kg/m^2.
Exclusion criteria:
- Known or suspected hypersensitivity to trial product(s) or related products.
- Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate contraceptive method.
- Participation in any clinical trial of an approved or non-approved investigational medicinal product within 90 days before screening.
- Any disorder, except for conditions associated with type 2 diabetes mellitus, which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol.
- Any episodes of diabetic ketoacidosis within the past 90 days prior to the day of screening and between screening and randomisation.
- Known hypoglycaemic unawareness as indicated by the Investigator according to Clarke's questionnaire question 8.
- Recurrent severe hypoglycaemic episodes within the last year as judged by the Investigator.
- Myocardial infarction, stroke, hospitalisation for unstable angina pectoris or transient ischaemic attack within 180 days prior to the day of screening and between screening and randomisation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Insulin 287 (with 100% loading dose)
Participants will receive insulin 287 injections once weekly (OW).
A unit to unit switch approach with an additional 100% loading dose of insulin 287 will be used.
|
Participants will receive subcutaneous (s.c.) injections of Insulin 287 OW for 16 weeks.
Other Names:
|
|
Experimental: Insulin 287 (without loading dose)
Participants will receive insulin 287 injections OW.
A unit to unit switch approach without loading dose of insulin 287 will be used.
|
Participants will receive subcutaneous (s.c.) injections of Insulin 287 OW for 16 weeks.
Other Names:
|
|
Active Comparator: Insulin glargine U100
Participants will receive insulin glargine U100 once daily (OD).
|
Participants will receive s.c.
injections of insulin glargine OD for 16 weeks
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Time in Target Range 3.9-10.0 mmol/L (70-180 Milligrams Per Deciliter (mg/dL)) Measured Using CGM (Continuous Glucose Monitoring)
Time Frame: During the last 2 weeks of treatment (week 15 and 16)
|
The percentage of time spent in glycaemic target range was calculated as 100 times the number of recorded measurements in glycaemic target range 3.9-10.0
mmol/L (70-180 mg/dL), both inclusive divided by the total number of recorded measurements.
The endpoint was evaluated based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was on treatment with trial product, excluding any period after initiation of a non-randomised insulin treatment (rescue medication).
|
During the last 2 weeks of treatment (week 15 and 16)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Glycosylated Haemoglobin (HbA1c)
Time Frame: From baseline week 0 (V2) to week 16 (V18)
|
Estimated mean change from baseline (week 0) in HbA1c at week 16 is presented.
The endpoint was evaluated based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was on treatment with trial product, excluding any period after initiation of a non-randomised insulin treatment (rescue medication).
|
From baseline week 0 (V2) to week 16 (V18)
|
|
Change in Fasting Plasma Glucose (FPG)
Time Frame: From baseline week 0 (V2) to week 16 (V18)
|
Estimated mean change from baseline (week 0) in FPG at week 16 is presented.
The endpoint was evaluated based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was on treatment with trial product, excluding any period after initiation of a non-randomised insulin treatment (rescue medication).
|
From baseline week 0 (V2) to week 16 (V18)
|
|
Change in Body Weight
Time Frame: From baseline week 0 (V2) to week 16 (V18)
|
Estimated mean change from baseline (week 0) in body weight at week 16 is presented.
The endpoint was evaluated based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was on treatment with trial product, excluding any period after initiation of a non-randomised insulin treatment (rescue medication).
|
From baseline week 0 (V2) to week 16 (V18)
|
|
Weekly Insulin Dose
Time Frame: During the last 2 weeks of treatment (week 15 and 16)
|
Estimated mean average weekly insulin dose during the last 2 weeks of treatment is presented.
The endpoint was evaluated based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was on treatment with trial product, excluding any period after initiation of a non-randomised insulin treatment (rescue medication).
|
During the last 2 weeks of treatment (week 15 and 16)
|
|
Number of Treatment-emergent Adverse Events (TEAEs)
Time Frame: From baseline week 0 (V2) to week 21 (V20)
|
An adverse event(AE) is any untoward medical occurrence in a clinical trial subject administered or using a medicinal product, whether or not considered related to the medicinal product or usage..
A TEAE was defined as an event that had onset date (or increase in severity) during the on-treatment observation period.
The on-treatment observation period was the time period from first dose of trial product until the follow-up visit or the last date on trial product + 5 weeks for once daily insulin and +6 weeks for once weekly insulin.
Safety analysis set (SAS) included all subjects exposed to at least one dose of trial product.
|
From baseline week 0 (V2) to week 21 (V20)
|
|
Number of Severe Hypoglycaemic Episodes (Level 3)
Time Frame: From baseline week 0 (V2) to week 16 (V18)
|
Severe hypoglycaemic episodes (level 3) were defined as episodes that were associated with severe cognitive impairment requiring external assistance for recovery.
Number of severe hypoglycaemic episodes that occurred during weeks 0-16 are presented.
|
From baseline week 0 (V2) to week 16 (V18)
|
|
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Below 3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)
Time Frame: From baseline week 0 (V2) to week 16 (V18)
|
Clinically significant hypoglycaemic episodes (level 2) were defined as episodes that were sufficiently low to indicate serious, clinically important hypoglycaemia with plasma glucose value of <3.0 mmol/L (54 mg/dL).
Severe hypoglycaemic episodes (level 3) were defined as episodes that were associated with severe cognitive impairment requiring external assistance for recovery.
Number of clinically significant hypoglycaemic episodes (level 2), confirmed by blood glucose (BG)meter or severe hypoglycaemic episodes (level 3) that occured during weeks 0-16 are presented.
|
From baseline week 0 (V2) to week 16 (V18)
|
|
Number of Hypoglycaemic Alert Episodes(Level 1) (Greater Than or Equal to 3.0 and Below 3.9 mmol/L (Greater Than or Equal to 54 and Below 70 mg/dL), Confirmed by BG Meter)
Time Frame: From baseline week 0 (V2) to week 16 (V18)
|
Hypoglycaemia alert value (level 1) was defined as episodes that were sufficiently low for treatment with fast-acting carbohydrate and dose adjustment of glucose-lowering therapy.
Number of hypoglycaemic alert episodes (level 1) (equal to or above 3.0 and below 3.9 mmol/L (equal to or above 54 and below 70 mg/dL), confirmed by BG meter) that occured during weeks 0-16 are presented.
|
From baseline week 0 (V2) to week 16 (V18)
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NN1436-4466
- U1111-1219-5541 (Other Identifier: World Health Organization (WHO))
- 2018-003407-18 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.